Insmed Incorporated

NASDAQ:INSM

Biotechnology

Healthcare
$119.80 -2.77%

-$2.73 today

Market cap
$26.28B
Beta
0.77
P/E (TTM)
-17.4
EPS (TTM)
-$5.49
52W Low $90.39High $212.75

Volume 1.94M

Average 3.31M

INSM Operating Margin

Operating income as a percentage of revenue, showing the profitability of core operations.

Insmed IncorporatedNASDAQ: INSM

Operating Margin · Q2 FY2026 · quarter ended Jun 2026

Operating margin widens to -0.4%

Operating margin was -0.4% in Q2 FY2026, up 290.9 pp from a year earlier. On a trailing-twelve-month basis it was -71.9%, up 180.5 pp year over year. Over 3 fiscal years it narrowed by 7.7 pp.

Context

  • Operating margin widened in 1 of the last 3 fiscal years.

What to watch

Whether operating margin reaches the consensus estimate from 15 analysts of -15.1% for the fiscal year ending Dec 2026, up from -194.0% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
-0.4%+65.1 pp QoQ
Last fiscal yearDec 2025
-194.0%+47.4 pp YoY
LTMJun 2026
-71.9%+180.5 pp YoY
Operating Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+290.9 pp+244.5 pp-46.4 pp
1 year+47.4 pp+179.0 pp+131.5 pp
3 years-7.7 pp+220.2 pp+227.9 pp
5 years+238.7 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Operating Margin history

Percent of revenue · from the income statement

Latest · FY2025
-194.0%
Year-over-year change
+47.4pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Operating Margin vs competitors

How INSM compares with its peers on the latest reported figures

  • INSM's LTM Jun 2026 operating margin of -71.9% is the lowest of the 4 companies compared; the peer median is 37.4%.
  • Its year-over-year change of +180.5 pp is the 2nd highest of 4, against a peer median of +77.0 pp.
  • Over three fiscal years its change of -7.7 pp compares with a peer median of +166.8 pp.
INSM Competitors Peer median
Operating Margin for INSM and competitors
Company Period LTM level YoY 3-year change
UTHRUnited Therapeutics CorporationLTM Jun 202644.5% -2.6 pp-2.9 pp
LQDALiquidia CorporationLTM Jun 202637.4% +752.8 pp+210.9 pp
TBPHTheravance Biopharma, Inc.LTM Mar 20260.1% +77.0 pp+166.8 pp
INSMInsmed IncorporatedLTM Jun 2026-71.9% +180.5 pp-7.7 pp
AVLNAvalyn Pharma Inc. Common Stock—— ——
Peer median (excluding INSM) 37.4%+77.0 pp+166.8 pp

Competitors are the stored peer set for INSM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue188.46M245.36M305.21M363.71M606.42M
Cost of Revenue44.15M55.13M65.57M85.74M124.88M
Gross Profit144.31M190.23M239.64M277.97M481.55M
Gross Margin76.6%77.5%78.5%76.4%79.4%
Research & Development272.74M397.52M571.01M598.37M771.09M
Selling, General & Admin234.27M265.78M344.5M461.12M701.17M
Operating Expenses519.4M647.55M949.26M1.16B1.66B
Depreciation & Amortization14.18M10.33M10.58M11.01M16.45M
EBITDA(383.65M)(447.37M)(660.18M)(818.79M)(1.17B)
EBITDA Margin-203.6%-182.3%-216.3%-225.1%-193.2%
Operating Income(375.09M)(457.32M)(709.63M)(878.25M)(1.18B)
Operating Margin-199.0%-186.4%-232.5%-241.5%-194.0%
Interest Income174K11.08M42.13M53.31M60.66M
Interest Expense40.47M26.45M81.69M84.91M83.8M
Other Income / Expenses(61.32M)(22.83M)(37.39M)(31.81M)(95.02M)
Income Before Tax(436.41M)(480.15M)(747.01M)(910.07M)(1.27B)
Pre-Tax Margin-231.6%-195.7%-244.8%-250.2%-209.7%
Income Tax Expense(1.76M)1.38M2.56M3.71M5.03M
Net Income(434.65M)(481.53M)(749.57M)(913.77M)(1.28B)
Net Margin-230.6%-196.3%-245.6%-251.2%-210.5%
EPS (Basic)(3.88)(3.91)(5.34)(5.57)(6.41)
EPS (Diluted)(3.88)(3.91)(5.34)(5.57)(6.41)
Weighted Avg Shares112.11M123.04M140.43M164.04M213.64M
Weighted Avg Shares (Diluted)112.11M123.04M140.43M164.04M213.64M

Insmed Incorporated

NASDAQ:INSM

Intrinsic Alpha fair value

Locked

Current Price

$119.80

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.